Nicolas Benech
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Nicolas Benech has a total of 151 co-authors. Here are the top co-authors by number of shared publications:
- Harry Sokol
Sorbonne Université, INSERM UMRS-938, Centre de Recherche Saint-Antoine, CRSA, AP-HP, F-75012 Paris, France; Gut, Liver & Microbiome Research (GLIMMER) FHU, Paris, France; Université Paris-Saclay, INRAE, AgroParisTech, Micalis Institute, Jouy-en-Josas, France; Department of Gastroenterology, Saint Antoine Hospital, APHP, Paris, France
4 shared publications Jean-Christophe Saurin
Gastroenterology Unit, Edouard Herriot Hospital, Hospices Civils de Lyon, Lyon, France
3 shared publicationsDaniel Orbach
SIREDO Oncology Center (Care, Innovation and Research for Children, Adolescents and Young Adults with Cancer), Institut Curie, Paris, France
2 shared publicationsFrédéric Barbut
French Faecal Transplant Group (GFTF) France
2 shared publications- Hector Hernandez-Vargas
Cancer Research Center of Lyon (CRCL) INSERM 1052, CNRS 5286, Lyon, France
2 shared publications - Julien C. Marie
TGF-beta and Immune Response (Université Claude Bernard Lyon 1, INSERM U1052, CNRS UMR5286, Centre Léon Bérard), Equipe labellisée Ligue nationale contre le cancer, Cancer Research Center of Lyon, Lyon, France
2 shared publications
Latest Publications
- 6 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Etude du rôle de la signalisation du TGF-beta au sein des lymphocytes T dans la tolérance au microbiote intestinal
Avec 3. 1013 cellules humaines pour 3.8.1013 bactéries, plus de la moitié des cellules de notre corps est constituée d’éléments porteurs d’antigène potentiellement immunogènes. Une régulation fine de la réponse immune intra-muqueuse visant à empêcher une réaction inflammatoire délétère et maintenir un état symbiotique entre le microbiote digestif et son hôte existe donc chez les mammifères. Les mécanismes mis en jeu dans cette régulation cruciale restent cependant mal connus. Au cours de mon travail de thèse, j’ai exploré le rôle du TGF-ß, une cytokine hautement immuno-régulatrice, dans le maintien de la tolérance des lymphocytes T au microbiote intestinal. Au moyen d’approches génétiques, j’ai pu montrer que l’ablation sélective dans les lymphocytes T de SMAD4 et TRIM-33, deux acteurs de la signalisation du TGF-ß, conduit à une gastro-entérocolite diffuse chronique sous la dépendance du microbiote intestinal puisque résolutive sous traitement antibiotique. Cette inflammation chronique est associée à une forte augmentation de la phosphorylation de STAT-3 au sein de l‘épithélium associée au développement de cancer colo-rectal (CCR). L'étude du profil immunitaire montre que cette altération de la signalisation du TGF-ß au sein des lymphocytes T induit un défaut intrinsèque de génération des lymphocytes T régulateurs FOXP3+RORgammat+ au niveau de la lamina propria et une activation constitutive des lymphocytes T effecteurs CD8+ et CD4+ associée à la production d’interleukine(IL)-17 et d’interferon-gamma. Cette activation des lymphocytes T est associée à une modification de la composition du microbiote intestinal dont le transfert n’est pas suffisant pour entrainer une inflammation chronique ou induire un CCR chez les souris de type sauvage. Ainsi l'altération combinée de la signalisation du TGF-ß dans les cellules T et la présence de bactéries commensales sont responsables de l’inflammation colique chronique conduisant à une transformation tumorale. Par ailleurs l’apport d’anti-IL-17 prévient l‘inflammation STAT-3 dépendante et les signes de transformation. Ainsi, ce travail révèle que le signal du TGF-ß au sein spécifiquement des lymphocytes T est indispensable au maintien d’une tolérance vis-à-vis du microbiote intestinal et prévient d’une colite chronique pouvant évoluer en CCR.
- 6 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Etude du rôle de la signalisation du TGF-beta au sein des lymphocytes T dans la tolérance au microbiote intestinal
Avec 3. 1013 cellules humaines pour 3.8.1013 bactéries, plus de la moitié des cellules de notre corps est constituée d’éléments porteurs d’antigène potentiellement immunogènes. Une régulation fine de la réponse immune intra-muqueuse visant à empêcher une réaction inflammatoire délétère et maintenir un état symbiotique entre le microbiote digestif et son hôte existe donc chez les mammifères. Les mécanismes mis en jeu dans cette régulation cruciale restent cependant mal connus. Au cours de mon travail de thèse, j’ai exploré le rôle du TGF-ß, une cytokine hautement immuno-régulatrice, dans le maintien de la tolérance des lymphocytes T au microbiote intestinal. Au moyen d’approches génétiques, j’ai pu montrer que l’ablation sélective dans les lymphocytes T de SMAD4 et TRIM-33, deux acteurs de la signalisation du TGF-ß, conduit à une gastro-entérocolite diffuse chronique sous la dépendance du microbiote intestinal puisque résolutive sous traitement antibiotique. Cette inflammation chronique est associée à une forte augmentation de la phosphorylation de STAT-3 au sein de l‘épithélium associée au développement de cancer colo-rectal (CCR). L'étude du profil immunitaire montre que cette altération de la signalisation du TGF-ß au sein des lymphocytes T induit un défaut intrinsèque de génération des lymphocytes T régulateurs FOXP3+RORgammat+ au niveau de la lamina propria et une activation constitutive des lymphocytes T effecteurs CD8+ et CD4+ associée à la production d’interleukine(IL)-17 et d’interferon-gamma. Cette activation des lymphocytes T est associée à une modification de la composition du microbiote intestinal dont le transfert n’est pas suffisant pour entrainer une inflammation chronique ou induire un CCR chez les souris de type sauvage. Ainsi l'altération combinée de la signalisation du TGF-ß dans les cellules T et la présence de bactéries commensales sont responsables de l’inflammation colique chronique conduisant à une transformation tumorale. Par ailleurs l’apport d’anti-IL-17 prévient l‘inflammation STAT-3 dépendante et les signes de transformation. Ainsi, ce travail révèle que le signal du TGF-ß au sein spécifiquement des lymphocytes T est indispensable au maintien d’une tolérance vis-à-vis du microbiote intestinal et prévient d’une colite chronique pouvant évoluer en CCR.
- Open Access
- 4 December 2025
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 14, e85154
Effectiveness of Different Methods of Interdental Hygiene in Daily Practice Among Young Adults: Protocol for a Randomized, Single-Blind Controlled Trial
Background: Interdental spaces are particularly susceptible to biofilm accumulation and gingival inflammation, which contribute to periodontal diseases and their systemic associations. While interdental brushes (IDBs) are recognized as the most effective method of interdental cleaning, their efficacy depends on proper adaptation to the interdental space. Calibration with a colorimetric probe may enhance their effectiveness and comfort. However, evidence directly comparing calibrated and noncalibrated IDBs, especially in young adults, a key target group for preventive strategies, remains limited. The Hygiene of Interdental Junctions in Adults (HIJA) trial was designed to address this gap. Objective: This protocol aims to compare the clinical, microbiological, and acceptability outcomes associated with calibrated versus noncalibrated IDBs in young adults, focusing on interdental inflammation, periodontal indices, and microbiota composition. Methods: The HIJA trial is a monocentric, randomized, controlled, single-blind, and parallel-arm study. Overall, 50 healthy, nonsmoking adults aged 18‐30 years will be randomized (1:1) to receive either calibrated or noncalibrated IDBs. Participants will perform daily interdental cleaning in addition to conventional toothbrushing for 3 months. The primary outcome will be the reduction in interdental inflammation, expressed as the change in bleeding on probing at 3 months. Secondary outcomes will assess differences in interdental microbiota composition (16S ribosomal RNA sequencing), periodontal indices (plaque index, gingival index, probing depth, and clinical attachment loss), and user acceptability measured through the Theoretical Framework of Acceptability questionnaire at 1, 2, and 3 months. Results: The HIJA trial will generate evidence on whether calibrated IDBs provide additional benefits over noncalibrated brushes in reducing interdental inflammation and improving oral health in young adults. Conclusions: HIJA findings could contribute to the implementation of clinical guidelines and preventive strategies for interdental hygiene in daily practice.
- 4 December 2025
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 14, e85154
Open AccessEffectiveness of Different Methods of Interdental Hygiene in Daily Practice Among Young Adults: Protocol for a Randomized, Single-Blind Controlled Trial
Background: Interdental spaces are particularly susceptible to biofilm accumulation and gingival inflammation, which contribute to periodontal diseases and their systemic associations. While interdental brushes (IDBs) are recognized as the most effective method of interdental cleaning, their efficacy depends on proper adaptation to the interdental space. Calibration with a colorimetric probe may enhance their effectiveness and comfort. However, evidence directly comparing calibrated and noncalibrated IDBs, especially in young adults, a key target group for preventive strategies, remains limited. The Hygiene of Interdental Junctions in Adults (HIJA) trial was designed to address this gap. Objective: This protocol aims to compare the clinical, microbiological, and acceptability outcomes associated with calibrated versus noncalibrated IDBs in young adults, focusing on interdental inflammation, periodontal indices, and microbiota composition. Methods: The HIJA trial is a monocentric, randomized, controlled, single-blind, and parallel-arm study. Overall, 50 healthy, nonsmoking adults aged 18‐30 years will be randomized (1:1) to receive either calibrated or noncalibrated IDBs. Participants will perform daily interdental cleaning in addition to conventional toothbrushing for 3 months. The primary outcome will be the reduction in interdental inflammation, expressed as the change in bleeding on probing at 3 months. Secondary outcomes will assess differences in interdental microbiota composition (16S ribosomal RNA sequencing), periodontal indices (plaque index, gingival index, probing depth, and clinical attachment loss), and user acceptability measured through the Theoretical Framework of Acceptability questionnaire at 1, 2, and 3 months. Results: The HIJA trial will generate evidence on whether calibrated IDBs provide additional benefits over noncalibrated brushes in reducing interdental inflammation and improving oral health in young adults. Conclusions: HIJA findings could contribute to the implementation of clinical guidelines and preventive strategies for interdental hygiene in daily practice.
- Open Access
- 19 April 2025
- Published by Wiley in United European Gastroenterology Journal
- Vol. 13 (8) , 1480-1490
Faecalibacterium Diversity in the Gut Microbiome of Crohn's Disease Patients
Faecalibacterium has recently garnered attention for its potential health implications. To better understand its role, we developed and assessed real‐time PCR assays for detecting and quantifying various Faecalibacterium species in human stool samples from both healthy individuals and Crohn's disease patients, either in flare or remission. The assays targeted the Microbial Anti‐inflammatory Molecule (MAM) genes, which encode MAM proteins. These assays demonstrated 100% species‐specificity using strains from six Faecalibacterium species: Faecalibacterium prausnitzii, Faecalibacterium taiwanense, Faecalibacterium duncaniae, Faecalibacterium longum, Faecalibacterium hattori, and Faecalibacterium CNCM4541. They also showed high sensitivity with detection limits of 10^5 bacteria per gram of sample. In healthy individuals, the different Faecalibacterium species varied in abundance. F. taiwanense, F. duncaniae, and F. longum were the most prevalent, around 10^10 bacteria/g of stool. In contrast, F. hattori and CNCM4541 were less abundant, with 10^7 bacteria/g. Despite its low abundance, F. hattori was present in all healthy subjects, while CNCM4541 was detected in only 50% of them. Notably, F. taiwanense, F. duncaniae, and F. longum were found in all healthy individuals. In Crohn's disease patients, both in flare and remission, a decrease in Faecalibacterium species was observed, with no recovery in remission. The most abundant species in Crohn's disease patients were F. prausnitzii and F. duncaniae, around 10^7 bacteria/g, while F. longum, F. hattori, and F. taiwanense were present at lower levels (10^6 bacteria/g), and CNCM4541 was no longer detected. Interestingly, F. prausnitzii showed a smaller decrease in abundance compared with other species. Moreover, F. prausnitzii was significantly more prevalent in patients in remission than in those in flare, suggesting that it may be more resistant to inflammation. These findings highlight the importance of accurately characterizing and quantifying Faecalibacterium species to better understand their role in health and disease.
- 19 April 2025
- Published by Wiley in United European Gastroenterology Journal
- Vol. 13 (8) , 1480-1490
Open AccessFaecalibacterium Diversity in the Gut Microbiome of Crohn's Disease Patients
Faecalibacterium has recently garnered attention for its potential health implications. To better understand its role, we developed and assessed real‐time PCR assays for detecting and quantifying various Faecalibacterium species in human stool samples from both healthy individuals and Crohn's disease patients, either in flare or remission. The assays targeted the Microbial Anti‐inflammatory Molecule (MAM) genes, which encode MAM proteins. These assays demonstrated 100% species‐specificity using strains from six Faecalibacterium species: Faecalibacterium prausnitzii, Faecalibacterium taiwanense, Faecalibacterium duncaniae, Faecalibacterium longum, Faecalibacterium hattori, and Faecalibacterium CNCM4541. They also showed high sensitivity with detection limits of 10^5 bacteria per gram of sample. In healthy individuals, the different Faecalibacterium species varied in abundance. F. taiwanense, F. duncaniae, and F. longum were the most prevalent, around 10^10 bacteria/g of stool. In contrast, F. hattori and CNCM4541 were less abundant, with 10^7 bacteria/g. Despite its low abundance, F. hattori was present in all healthy subjects, while CNCM4541 was detected in only 50% of them. Notably, F. taiwanense, F. duncaniae, and F. longum were found in all healthy individuals. In Crohn's disease patients, both in flare and remission, a decrease in Faecalibacterium species was observed, with no recovery in remission. The most abundant species in Crohn's disease patients were F. prausnitzii and F. duncaniae, around 10^7 bacteria/g, while F. longum, F. hattori, and F. taiwanense were present at lower levels (10^6 bacteria/g), and CNCM4541 was no longer detected. Interestingly, F. prausnitzii showed a smaller decrease in abundance compared with other species. Moreover, F. prausnitzii was significantly more prevalent in patients in remission than in those in flare, suggesting that it may be more resistant to inflammation. These findings highlight the importance of accurately characterizing and quantifying Faecalibacterium species to better understand their role in health and disease.
- Open Access
- 10 October 2024
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 61 (1) , 159-167
Impact of Clinical and Pharmacological Parameters on Faecal Microbiota Transplantation Outcome in Clostridioides difficile Infections: Results of a 5‐Year French National Survey
Background: Detailed comparative assessment of procedure‐related factors associated with faecal microbiota transplantation (FMT) efficacy in Clostridioides difficile infection (CDI) is limited.Aims: We took advantage of the differences in procedures at the various French FMT centres to determine clinical and procedure‐related factors associated with FMT success in CDI.Methods: We performed a nationwide retrospective multicentre cohort study. All FMTs performed within The French Faecal Transplant Group for CDI from 2018 to 2022 were included. Clinical data were collected retrospectively from recipient medical files, characteristics of stool transplant preparations were prospectively collected by each Pharmacy involved. Univariate and multivariate analyses were performed using Fisher's test and multiple logistic regression.Results: Six hundred fifty‐eight FMTs were performed for 617 patients in 17 centres. The overall efficacy of FMT was 84.3% (520/617), with 0.5% of severe adverse events possibly related to FMT (3/658). Forty‐seven patients were treated at the first recurrence of CDI with a similar success rate (85.1%). Severe chronic kidney disease (CKD; OR: 2.18, 95%CI [1.20–3.88]), non‐severe refractory CDI (OR: 15.35, [1.94–318.2]), the use of ≥ 80% glycerol (OR: 2.52, [1.11–5.67]), insufficient bowel cleansing (OR: 5.47, [1.57–20.03]) and partial FMT retention (OR: 9.97, [2.62–48.49]) were associated with CDI recurrence within 8 weeks.Conclusions: Conditions of transplant manufacturing, bowel cleansing, and a route of delivery tailored to the patient's characteristics are key factors in optimising FMT efficacy. FMT at first recurrence showed high success in real‐life practice, whereas it had lower efficacy in severe CDI and non‐severe refractory CDI.
- 10 October 2024
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 61 (1) , 159-167
Open AccessImpact of Clinical and Pharmacological Parameters on Faecal Microbiota Transplantation Outcome in Clostridioides difficile Infections: Results of a 5‐Year French National Survey
Background: Detailed comparative assessment of procedure‐related factors associated with faecal microbiota transplantation (FMT) efficacy in Clostridioides difficile infection (CDI) is limited.Aims: We took advantage of the differences in procedures at the various French FMT centres to determine clinical and procedure‐related factors associated with FMT success in CDI.Methods: We performed a nationwide retrospective multicentre cohort study. All FMTs performed within The French Faecal Transplant Group for CDI from 2018 to 2022 were included. Clinical data were collected retrospectively from recipient medical files, characteristics of stool transplant preparations were prospectively collected by each Pharmacy involved. Univariate and multivariate analyses were performed using Fisher's test and multiple logistic regression.Results: Six hundred fifty‐eight FMTs were performed for 617 patients in 17 centres. The overall efficacy of FMT was 84.3% (520/617), with 0.5% of severe adverse events possibly related to FMT (3/658). Forty‐seven patients were treated at the first recurrence of CDI with a similar success rate (85.1%). Severe chronic kidney disease (CKD; OR: 2.18, 95%CI [1.20–3.88]), non‐severe refractory CDI (OR: 15.35, [1.94–318.2]), the use of ≥ 80% glycerol (OR: 2.52, [1.11–5.67]), insufficient bowel cleansing (OR: 5.47, [1.57–20.03]) and partial FMT retention (OR: 9.97, [2.62–48.49]) were associated with CDI recurrence within 8 weeks.Conclusions: Conditions of transplant manufacturing, bowel cleansing, and a route of delivery tailored to the patient's characteristics are key factors in optimising FMT efficacy. FMT at first recurrence showed high success in real‐life practice, whereas it had lower efficacy in severe CDI and non‐severe refractory CDI.
- Open Access
- 31 July 2024
- Published by Elsevier in Best Practice & Research Clinical Gastroenterology
- Vol. 72, 101942
Gut microbiota in inflammation and colorectal cancer: A potential Toolbox for Clinicians
- 31 July 2024
- Published by Elsevier in Best Practice & Research Clinical Gastroenterology
- Vol. 72, 101942
Open AccessGut microbiota in inflammation and colorectal cancer: A potential Toolbox for Clinicians
- Open Access
- 26 July 2024
- Published by Springer Nature in Nature Immunology
- Vol. 25 (9) , 1637-1649
An intestinal TH17 cell-derived subset can initiate cancer
Approximately 25% of cancers are preceded by chronic inflammation that occurs at the site of tumor development. However, whether this multifactorial oncogenic process, which commonly occurs in the intestines, can be initiated by a specific immune cell population is unclear. Here, we show that an intestinal T cell subset, derived from interleukin-17 (IL-17)-producing helper T (T H 17) cells, induces the spontaneous transformation of the intestinal epithelium. This subset produces inflammatory cytokines, and its tumorigenic potential is not dependent on IL-17 production but on the transcription factors KLF6 and T-BET and interferon-γ. The development of this cell type is inhibited by transforming growth factor-β1 (TGFβ1) produced by intestinal epithelial cells. TGFβ signaling acts on the pretumorigenic T H 17 cell subset, preventing its progression to the tumorigenic stage by inhibiting KLF6-dependent T-BET expression. This study therefore identifies an intestinal T cell subset initiating cancer.
- 26 July 2024
- Published by Springer Nature in Nature Immunology
- Vol. 25 (9) , 1637-1649
Open AccessAn intestinal TH17 cell-derived subset can initiate cancer
Approximately 25% of cancers are preceded by chronic inflammation that occurs at the site of tumor development. However, whether this multifactorial oncogenic process, which commonly occurs in the intestines, can be initiated by a specific immune cell population is unclear. Here, we show that an intestinal T cell subset, derived from interleukin-17 (IL-17)-producing helper T (T H 17) cells, induces the spontaneous transformation of the intestinal epithelium. This subset produces inflammatory cytokines, and its tumorigenic potential is not dependent on IL-17 production but on the transcription factors KLF6 and T-BET and interferon-γ. The development of this cell type is inhibited by transforming growth factor-β1 (TGFβ1) produced by intestinal epithelial cells. TGFβ signaling acts on the pretumorigenic T H 17 cell subset, preventing its progression to the tumorigenic stage by inhibiting KLF6-dependent T-BET expression. This study therefore identifies an intestinal T cell subset initiating cancer.
- Open Access
- 3 April 2024
- Published by Wiley in United European Gastroenterology Journal
- Vol. 12 (5) , 535-536
Decision‐analytic models based on real‐world data to assess treatment sequencing in inflammatory bowel disease: A complementary approach to clinical trials
- 3 April 2024
- Published by Wiley in United European Gastroenterology Journal
- Vol. 12 (5) , 535-536
Open AccessDecision‐analytic models based on real‐world data to assess treatment sequencing in inflammatory bowel disease: A complementary approach to clinical trials
- Top Cited Papers
- 27 March 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 16 (740) , eadl6149
The gut microbiota posttranslationally modifies IgA1 in autoimmune glomerulonephritis
Mechanisms underlying the disruption of self-tolerance in acquired autoimmunity remain unclear. Immunoglobulin A (IgA) nephropathy is an acquired autoimmune disease where deglycosylated IgA1 (IgA subclass 1) auto-antigens are recognized by IgG auto-antibodies, forming immune complexes that are deposited in the kidneys, leading to glomerulonephritis. In the intestinal microbiota of patients with IgA nephropathy, there was increased relative abundance of mucin-degrading bacteria, including Akkermansia muciniphila . IgA1 was deglycosylated by A. muciniphila both in vitro and in the intestinal lumen of mice. This generated neo-epitopes that were recognized by autoreactive IgG from the sera of patients with IgA nephropathy. Mice expressing human IgA1 and the human Fc α receptor I (α1 KI -CD89 tg ) that underwent intestinal colonization by A. muciniphila developed an aggravated IgA nephropathy phenotype. After deglycosylation of IgA1 by A. muciniphila in the mouse gut lumen, IgA1 crossed the intestinal epithelium into the circulation by retrotranscytosis and became deposited in the glomeruli of mouse kidneys. Human α-defensins—a risk locus for IgA nephropathy—inhibited growth of A. muciniphila in vitro. A negative correlation observed between stool concentration of α-defensin 6 and quantity of A. muciniphila in the guts of control participants was lost in patients with IgA nephropathy. This study demonstrates that gut microbiota dysbiosis contributes to generation of auto-antigens in patients with IgA nephropathy and in a mouse model of this disease.
- 27 March 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 16 (740) , eadl6149
Top Cited PapersThe gut microbiota posttranslationally modifies IgA1 in autoimmune glomerulonephritis
Mechanisms underlying the disruption of self-tolerance in acquired autoimmunity remain unclear. Immunoglobulin A (IgA) nephropathy is an acquired autoimmune disease where deglycosylated IgA1 (IgA subclass 1) auto-antigens are recognized by IgG auto-antibodies, forming immune complexes that are deposited in the kidneys, leading to glomerulonephritis. In the intestinal microbiota of patients with IgA nephropathy, there was increased relative abundance of mucin-degrading bacteria, including Akkermansia muciniphila . IgA1 was deglycosylated by A. muciniphila both in vitro and in the intestinal lumen of mice. This generated neo-epitopes that were recognized by autoreactive IgG from the sera of patients with IgA nephropathy. Mice expressing human IgA1 and the human Fc α receptor I (α1 KI -CD89 tg ) that underwent intestinal colonization by A. muciniphila developed an aggravated IgA nephropathy phenotype. After deglycosylation of IgA1 by A. muciniphila in the mouse gut lumen, IgA1 crossed the intestinal epithelium into the circulation by retrotranscytosis and became deposited in the glomeruli of mouse kidneys. Human α-defensins—a risk locus for IgA nephropathy—inhibited growth of A. muciniphila in vitro. A negative correlation observed between stool concentration of α-defensin 6 and quantity of A. muciniphila in the guts of control participants was lost in patients with IgA nephropathy. This study demonstrates that gut microbiota dysbiosis contributes to generation of auto-antigens in patients with IgA nephropathy and in a mouse model of this disease.
- Open Access
- 9 January 2024
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 56 (S 01) , E213-E214
Cold snaring biopsies to increase screening efficacy during endoscopic surveillance of patients at high risk of diffuse gastric cancer
Diffuse gastric cancer (DGC) is a poorly differentiated adenocarcinoma of the stomach characterized by independent “signet-ring” cells that invade the gastric wall with mainly submucosal infiltration resulting in delayed diagnosis [1]. Mutations in the CDH1 gene, encoding E-cadherin, have been identified in families with multiple cases of gastric cancer, with a 50%–80% increased risk of DGC in carriers [2]. In cases with a proven constitutional CDH1 mutation, guidelines recommend prophylactic total gastrectomy between the ages of 20 and 30 years, or endoscopic surveillance if surgery is refused or postponed [3]. Given the multiple possible localizations and frequency of small carcinomatous foci, a minimum of 30 biopsies divided into six zones using standard forceps is recommended [3] [4]. However, multiple sampling of the gastric mucosa using conventional biopsy forceps still represents a limited surface area that can be analyzed. Increasing the size of the biopsy sample using cold snaring may increase diagnostic sensitivity. We report here the case of a 33-year-old patient with regular endoscopic surveillance after identification of a CDH1 mutation in a familial context. Gastroscopy and endoscopic ultrasound were performed, with no findings of macroscopic abnormalities, parietal thickening, or suspicious adenopathy ([Video 1]). To increase the size of the tissue sampled for histological analysis, 24 cold snaring biopsies (6 upper fundus, 6 body, 6 lower body, and 6 antrum) were performed. Pathological analysis revealed a single focal area of independent cell adenocarcinoma in the chorion (pTis) seen only in one sample. A gastrectomy was then performed, with a millimetric focal adenocarcinoma with signet-ring cells on the surgical specimens. Histopathological analysis was improved, with the average size of biopsy fragments being significantly larger with cold snaring than with standard forceps, and with a reduction in crush artifacts ([Fig. 1]). In conclusion, this case suggests that large samples obtained with cold snaring could potentially decrease the focal adenocarcinoma miss rate in CDH1 mutation carriers. Endoscopy_UCTN_Code_TTT_1AO_2AC Article published online: 01 March 2024 © 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/). Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 9 January 2024
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 56 (S 01) , E213-E214
Open AccessCold snaring biopsies to increase screening efficacy during endoscopic surveillance of patients at high risk of diffuse gastric cancer
Diffuse gastric cancer (DGC) is a poorly differentiated adenocarcinoma of the stomach characterized by independent “signet-ring” cells that invade the gastric wall with mainly submucosal infiltration resulting in delayed diagnosis [1]. Mutations in the CDH1 gene, encoding E-cadherin, have been identified in families with multiple cases of gastric cancer, with a 50%–80% increased risk of DGC in carriers [2]. In cases with a proven constitutional CDH1 mutation, guidelines recommend prophylactic total gastrectomy between the ages of 20 and 30 years, or endoscopic surveillance if surgery is refused or postponed [3]. Given the multiple possible localizations and frequency of small carcinomatous foci, a minimum of 30 biopsies divided into six zones using standard forceps is recommended [3] [4]. However, multiple sampling of the gastric mucosa using conventional biopsy forceps still represents a limited surface area that can be analyzed. Increasing the size of the biopsy sample using cold snaring may increase diagnostic sensitivity. We report here the case of a 33-year-old patient with regular endoscopic surveillance after identification of a CDH1 mutation in a familial context. Gastroscopy and endoscopic ultrasound were performed, with no findings of macroscopic abnormalities, parietal thickening, or suspicious adenopathy ([Video 1]). To increase the size of the tissue sampled for histological analysis, 24 cold snaring biopsies (6 upper fundus, 6 body, 6 lower body, and 6 antrum) were performed. Pathological analysis revealed a single focal area of independent cell adenocarcinoma in the chorion (pTis) seen only in one sample. A gastrectomy was then performed, with a millimetric focal adenocarcinoma with signet-ring cells on the surgical specimens. Histopathological analysis was improved, with the average size of biopsy fragments being significantly larger with cold snaring than with standard forceps, and with a reduction in crush artifacts ([Fig. 1]). In conclusion, this case suggests that large samples obtained with cold snaring could potentially decrease the focal adenocarcinoma miss rate in CDH1 mutation carriers. Endoscopy_UCTN_Code_TTT_1AO_2AC Article published online: 01 March 2024 © 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/). Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 13 December 2023
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 30 (4) , 462-468
Update on microbiota-derived therapies for recurrent Clostridioides difficile infections
- 13 December 2023
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 30 (4) , 462-468
Update on microbiota-derived therapies for recurrent Clostridioides difficile infections